Rapport Therapeutics (RAPP) Financials

Balance sheets

Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 1, 2023Sep 1, 2023Jun 30, 2023Mar 31, 2023

Total Assets

$331.1 M(-4.3%)$346.1 M(+67.8%)$206.3 M(+32.7%)$155.4 M---

Current Assets

$325.9 M(-4.3%)$340.7 M(+71.4%)$198.7 M(+31.7%)$150.9 M---

Non Current Assets

$5.2 M(-4.2%)$5.4 M(-28.2%)$7.6 M(+66.1%)$4.6 M---

Total Liabilities

$8.0 M(-12.8%)$9.2 M(-96.3%)$245.9 M(+35.8%)$181.1 M---

Current Liabilities

$7.1 M(-12.3%)$8.1 M(-18.1%)$9.9 M(+12.3%)$8.8 M---

Long Term Liabilities

$931.0 K(-16.6%)$1.1 M(-99.5%)$236.0 M(+37.0%)$172.3 M---

Shareholders Equity

$323.1 M(-4.1%)$336.9 M(+950.0%)-$39.6 M(-54.6%)-$25.6 M---

Book Value

$323.1 M(-4.1%)$336.9 M(+950.0%)-$39.6 M(-54.6%)-$25.6 M---

Working Capital

$318.8 M(-4.1%)$332.6 M(+76.1%)$188.8 M(+32.9%)$142.1 M---

Cash And Cash Equivalents

$39.3 M(-64.3%)$110.2 M(+48.3%)$74.3 M(+5.8%)$70.2 M---

Accounts Payable

$1.3 M(-29.4%)$1.9 M(+29.5%)$1.4 M(-42.1%)$2.5 M---

Accounts Receivable

-------

Short Term Debt

$720.0 K(+2.4%)$703.0 K(+2.5%)$686.0 K(+2.4%)$670.0 K---

Long Term Debt

$931.0 K(-16.6%)$1.1 M(-13.9%)$1.3 M(-12.1%)$1.5 M---

Total Debt

$1.7 M(-9.3%)$1.8 M(-8.3%)$2.0 M(-7.5%)$2.1 M(+100.0%)$0.0(0%)$0.0(0%)$0.0

Debt To Equity

0.0(0%)0.0(+120.0%)-0.1(+37.5%)-0.1---

Current Ratio

45.9(+9.1%)42.1(+109.3%)20.1(+17.3%)17.1---

Quick Ratio

-------

Inventory

-------

Retained Earnings

-$103.8 M(-20.3%)-$86.2 M(-26.6%)-$68.1 M(-49.9%)-$45.4 M---

PB Ratio

14.3(-8.2%)15.6-----

Income statements

Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 1, 2023Sep 1, 2023Jun 30, 2023Mar 31, 2023

EPS

-$0.5(+70.6%)-$1.7(-80.8%)-$0.9(-146.0%)-$0.4(-6.1%)-$0.4(-35.9%)-$0.3(-4.3%)-$0.3

TTM EPS

-$3.5(-4.1%)-$3.4(-73.7%)-$1.9(-54.4%)-$1.3(-43.5%)-$0.9(-69.3%)-$0.5(-104.3%)-$0.3

Revenue

-------

TTM Revenue

-------

Total Expenses

$21.6 M(+4.0%)$20.8 M(+21.7%)$17.1 M(+15.6%)$14.8 M(+54.7%)$9.6 M(+44.3%)$6.6 M(+27.7%)$5.2 M

Operating Expenses

$21.6 M(+4.0%)$20.8 M(+21.7%)$17.1 M(+15.6%)$14.8 M(+54.7%)$9.6 M(+44.3%)$6.6 M(+27.7%)$5.2 M

Cost Of Goods Sold

-------

TTM Cost Of Goods Sold

-------

Gross Profit

-------

TTM Gross Profit

-------

Gross Margin

-------

Operating Profit

-$21.6 M(-4.0%)-$20.8 M(-21.7%)-$17.1 M(-15.6%)-$14.8 M(-54.7%)-$9.6 M(-44.3%)-$6.6 M(-27.7%)-$5.2 M

TTM Operating Profit

-$74.3 M(-19.4%)-$62.3 M(-29.5%)-$48.1 M(-32.9%)-$36.2 M(-69.2%)-$21.4 M(-80.9%)-$11.8 M(-127.7%)-$5.2 M

Operating Margin

-------

Net Income

-$17.5 M(+3.2%)-$18.1 M(+20.1%)-$22.7 M(-67.7%)-$13.5 M(-55.2%)-$8.7 M(-35.8%)-$6.4 M(-4.3%)-$6.1 M

TTM Net Income

-$71.8 M(-14.0%)-$63.0 M(-22.8%)-$51.3 M(-47.5%)-$34.8 M(-63.6%)-$21.3 M(-69.3%)-$12.6 M(-104.3%)-$6.1 M

Net Margin

-------

EBIT

-$21.6 M(-4.0%)-$20.8 M(-21.7%)-$17.1 M(-27.6%)-$13.4 M(-40.0%)-$9.6 M(-44.3%)-$6.6 M(-27.7%)-$5.2 M

TTM EBIT

-$72.9 M(-19.9%)-$60.8 M(-30.4%)-$46.7 M(-34.2%)-$34.8 M(-62.6%)-$21.4 M(-80.9%)-$11.8 M(-127.7%)-$5.2 M

EBITDA

-$21.4 M(-4.0%)-$20.6 M(-21.5%)-$16.9 M(-27.0%)-$13.3 M(-39.8%)-$9.5 M(-44.4%)-$6.6 M(-27.7%)-$5.2 M

TTM EBITDA

-$72.3 M(-19.7%)-$60.4 M(-30.1%)-$46.4 M(-33.9%)-$34.7 M(-62.5%)-$21.3 M(-81.0%)-$11.8 M(-127.7%)-$5.2 M

Selling, General & Administrative Expenses

$6.1 M(+19.3%)$5.1 M(+11.3%)$4.6 M(+53.3%)$3.0 M(+51.0%)$2.0 M(+3.9%)$1.9 M(+47.8%)$1.3 M

TTM SGA

$18.8 M(+28.0%)$14.7 M(+27.9%)$11.5 M(+40.3%)$8.2 M(+57.8%)$5.2 M(+62.0%)$3.2 M(+147.8%)$1.3 M

Depreciation And Amortization

$219.0 K(+5.3%)$208.0 K(+36.8%)$152.0 K(+186.8%)$53.0 K(+130.4%)$23.0 K(+9.5%)$21.0 K(+40.0%)$15.0 K

TTM D&A

$632.0 K(+45.0%)$436.0 K(+75.1%)$249.0 K(+122.3%)$112.0 K(+89.8%)$59.0 K(+63.9%)$36.0 K(+140.0%)$15.0 K

Interest Expense

-------

TTM Interest Expense

-------

Income Tax

$0.0(0%)$0.0(0%)$0.0(-100.0%)$6000.0(+500.0%)$1000.0(-50.0%)$2000.0(+100.0%)$1000.0

TTM Income Tax

$6000.0(-14.3%)$7000.0(-22.2%)$9000.0(-10.0%)$10.0 K(+150.0%)$4000.0(+33.3%)$3000.0(+200.0%)$1000.0

PE Ratio

-------

PS Ratio

-------

Cashflow statements

Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 1, 2023Sep 1, 2023Jun 30, 2023Mar 31, 2023

Cash From Operations

-$16.4 M(-0.4%)-$16.4 M(+7.2%)-$17.6 M(-70.1%)-$10.4 M(-91.0%)-$5.4 M(+17.8%)-$6.6 M(-37.5%)-$4.8 M

TTM CFO

-$60.7 M(-22.1%)-$49.7 M(-24.4%)-$40.0 M(-47.1%)-$27.2 M(-61.6%)-$16.8 M(-47.6%)-$11.4 M(-137.4%)-$4.8 M

Cash From Investing

-$53.0 M(+50.5%)-$107.1 M(-155.5%)-$41.9 M(+46.7%)-$78.7 M(-151171.1%)-$52.0 K(+39.5%)-$86.0 K(-41.0%)-$61.0 K

TTM CFI

-$280.7 M(-23.3%)-$227.7 M(-88.7%)-$120.7 M(-53.1%)-$78.9 M(-39528.1%)-$199.0 K(-35.4%)-$147.0 K(-141.0%)-$61.0 K

Cash From Financing

-$1.4 M(-100.9%)$159.4 M(+150.3%)$63.7 M(+45570.7%)-$140.0 K(-100.2%)$85.4 M(+94944.4%)-$90.0 K(-100.2%)$60.0 M

TTM CFF

$221.5 M(-28.1%)$308.2 M(+107.2%)$148.8 M(+2.5%)$145.1 M(-0.1%)$145.3 M(+142.5%)$59.9 M(-0.1%)$60.0 M

Free Cash Flow

-$16.6 M(+4.4%)-$17.3 M(+7.3%)-$18.7 M(-58.4%)-$11.8 M(-115.4%)-$5.5 M(+18.1%)-$6.7 M(-37.5%)-$4.9 M

TTM FCF

-$64.4 M(-20.8%)-$53.3 M(-24.9%)-$42.6 M(-48.0%)-$28.8 M(-69.3%)-$17.0 M(-47.4%)-$11.5 M(-137.5%)-$4.9 M

CAPEX

-------

TTM CAPEX

-------

Dividends Paid

-------

TTM Dividends Paid

-------

TTM Dividend Per Share

-------

TTM Dividend Yield

-------

Payout Ratio

-------